MediSapiens, world’s first software company for personalized cancer medicine in oncology clinics and drug development, completed US$ 1 million (€ 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.
MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world’s largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease – to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.
“The latest research - such as The Cancer Genome Atlas funded by the NIH – demonstrates that every patient’s cancer is a complex, unique combination of genetic mutations and abnormally expressed genes. The MediSapiens software gives personalized and clinically applicable insight into each patient’s cancer,” says Tommi Pisto, CEO and co-founder of MediSapiens.
“Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer. Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients,” comments professor Olli Kallioniemi, MediSapiens board member and director of the Institute for Molecular Medicine Finland (FIMM).
MediSapiens, the world’s first software company for personalized cancer medicine in oncology clinics and new drug development, hosts world’s largest unified gene expression database.
Veraventure, with assets under management exceeding € 100m, is one of the largest early stage funds in Nordic countries.
Eqvitec Partners is one of the largest technology oriented private equity firms in Northern Europe. The company was founded in 1997 and employs 10 investment professionals in Helsinki and Stockholm.
VTT Ventures Ltd is a development company that generates and develops spin-offs based on VTT’s technology.
Lifeline Ventures, a venture accelerator and early-stage investment fund, co-creates growth companies in health and technology. Being entrepreneurs, we are active team members for an early-stage venture for 12-24 months.